✦ LIBER ✦

Trastuzumab Retreatment after Relapse on Adjuvant Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Final Results of the Retreatment after Herceptin Adjuvant Trial

✍ Scribed by Láng, I.; Bell, R.; Feng, F.Y.; Lopez, R.I.; Jassem, J.; Semiglazov, V.; Al-Sakaff, N.; Heinzmann, D.; Chang, J.

Book ID: 121752490
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 448 KB
Volume: 26
Category: Article
ISSN: 1433-2981
DOI: 10.1016/j.clon.2013.08.011

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of Age on Breast Cancer Outcomes

Effect of Age on Breast Cancer Outcomes in Women With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From a Herceptin Adjuvant Trial

✍ Partridge, A. H.; Gelber, S.; Piccart-Gebhart, M. J.; Focant, F.; Scullion, M.; 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 157 KB

Phase II Study of the Antibody Drug Conj

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy

✍ Burris, H. A.; Rugo, H. S.; Vukelja, S. J.; Vogel, C. L.; Borson, R. A.; Limenta 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 176 KB

Overall Survival Benefit With Lapatinib

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

✍ Blackwell, K. L.; Burstein, H. J.; Storniolo, A. M.; Rugo, H. S.; Sledge, G.; Ak 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 203 KB

Multicenter Phase II Trial of Neoadjuvan

Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2–overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial

✍ Glück, S. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 72 KB

Seven-Year Follow-Up Assessment of Cardi

Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

✍ Zibelman, M.; Goldstein, L.J. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 54 KB